PMID- 12376263
OWN - NLM
STAT- MEDLINE
DCOM- 20030123
LR  - 20220127
IS  - 1000-2588 (Print)
IS  - 1000-2588 (Linking)
VI  - 22
IP  - 8
DP  - 2002 Aug
TI  - [Quantitative analysis of Sokal's risk index in relation to 2 therapy protocols: 
      their respective impact on clinical remission of chronic myeloid leukemia].
PG  - 729-30
AB  - OBJECTIVE: To quantitatively evaluate the impact of Sokal's risk index and that 
      of 2 therapy protocols on the clinical outcome of patients with chronic myeloid 
      leukemia (CML). METHODS: With the assistance of Access 2000 database of CML, 94 
      patients with CML were grouped on the basis of either different therapy protocols 
      utilizing harringtonine plus Ara-C (HA) vs hydroxyurea (Hu) or Sokal scores, and 
      the impact of therapy protocol and risk profile were quantitatively evaluated 
      respectively. RESULT: Treatment protocol utilizing HA was incapable of 
      lengthening the duration of chronic phase (DCP) of CML, regardless of its better 
      short-term effect than that of Hu. The impact of risk profile of the patients on 
      clinical remission rate and DCP was more significant than that of the therapy 
      protocols. CONCLUSION: HA should not be used as the first-line protocol in the 
      treatment of CML patients in chronic phase who have not received any previous 
      medical intervention. Patients should be categorized according to the risk 
      profile for choosing appropriate treatment protocol and making better clinical 
      judgement.
FAU - Du, Qing-Feng
AU  - Du QF
AD  - Department of Hematology, Nanfang Hospital, First Military Medical University, 
      Guanghou 510515, China.
FAU - Liu, Xiao-Li
AU  - Liu XL
FAU - Liu, Qi-Fa
AU  - Liu QF
FAU - Li, Rong
AU  - Li R
FAU - Chen, Qi
AU  - Chen Q
FAU - Zhou, Shu-Yun
AU  - Zhou SY
LA  - chi
PT  - Evaluation Study
PT  - Journal Article
PL  - China
TA  - Di Yi Jun Yi Da Xue Xue Bao
JT  - Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
JID - 9426110
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Harringtonines)
RN  - 04079A1RDZ (Cytarabine)
RN  - 088662H40F (harringtonin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Cytarabine/*therapeutic use
MH  - Female
MH  - Harringtonines/*therapeutic use
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Treatment Outcome
EDAT- 2002/10/12 04:00
MHDA- 2003/01/24 04:00
CRDT- 2002/10/12 04:00
PHST- 2002/10/12 04:00 [pubmed]
PHST- 2003/01/24 04:00 [medline]
PHST- 2002/10/12 04:00 [entrez]
PST - ppublish
SO  - Di Yi Jun Yi Da Xue Xue Bao. 2002 Aug;22(8):729-30.